Clexane Administration Guidelines
Platelet Count Thresholds
- The National Comprehensive Cancer Network recommends initiating Clexane when platelet count is ≥50,000/mm³ for prophylactic dosing and ≥100,000/mm³ for therapeutic dosing, with no specific INR threshold required before initiation 1
- Initiate Clexane when platelet count is ≥50,000/mm³ in hospitalized patients requiring thromboprophylaxis 2, 1
- Hold prophylactic enoxaparin if platelet count drops below 50,000/mm³ due to increased bleeding risk 1
- Monitor platelet count at least every 2-3 days for the first 14 days after initiation, then every 2 weeks thereafter 1
- Initiate therapeutic Clexane when platelet count is ≥100,000/mm³ for treatment of established DVT or PE 1
- Consider holding therapeutic anticoagulation if platelets fall below 50,000/mm³ unless thrombotic risk substantially outweighs bleeding risk 1
- Obtain baseline CBC with platelet count before initiating enoxaparin 1
INR Considerations
- No specific INR threshold is required before initiating enoxaparin - it can be started regardless of baseline INR 2, 1
- Obtain baseline PT/INR before starting therapy for reference 1
- When bridging from enoxaparin to warfarin: Overlap enoxaparin with warfarin for minimum 5-7 days and continue until INR is therapeutic (2.0-3.0) for 2 consecutive days 2
- When transitioning from warfarin to enoxaparin: Start enoxaparin when INR falls below therapeutic range 2
- Standard VTE treatment: INR 2.0-3.0 2
- Mechanical mitral valves: INR 2.5-3.5 3
Contraindications to Clexane Administration
- Active major bleeding is an absolute contraindication to Clexane administration 2, 1
- Severe thrombocytopenia (platelet count <50,000/mm³ for prophylaxis, <100,000/mm³ for therapeutic dosing) is an absolute contraindication to Clexane administration 1
- History of heparin-induced thrombocytopenia is an absolute contraindication to Clexane administration 3
Special Populations
- Cancer patients should receive Clexane for at least 3 months or as long as cancer is active or under treatment 1
- Post-surgical patients should continue Clexane for minimum 7-10 days; consider extended prophylaxis up to 4 weeks for high-risk patients 2
Dosing Adjustments
- Severe renal impairment (CrCl <30 mL/min): Reduce therapeutic dose to 1 mg/kg once daily instead of twice daily 2, 1, 4
- Age ≥75 years (for ACS patients): Reduce dose to 0.75 mg/kg every 12 hours without initial IV bolus 4
- Recent neuraxial anesthesia: Wait minimum 8-12 hours after epidural catheter removal before administering enoxaparin 2, 4
Transitioning from Heparin Infusion to Enoxaparin – Evidence‑Based Recommendations
Dosing Protocol
- Standard therapeutic regimen: Enoxaparin 1 mg/kg administered subcutaneously every 12 hours is the preferred dosing for most patients switching from therapeutic unfractionated heparin. (American College of Cardiology/American Heart Association guideline) 5
- Age‑specific adjustment for elderly ACS patients: In patients aged ≥ 75 years, reduce the dose to 0.75 mg/kg every 12 hours and omit any initial intravenous bolus. (ACC/AHA) 6
Renal Function Considerations
- Severe renal impairment (creatinine clearance < 30 mL/min): Mandatory dose reduction to 1 mg/kg once daily (instead of twice daily) to avoid drug accumulation and excess bleeding risk. (ACC/AHA) 7
- Moderate or normal renal function (creatinine clearance ≥ 30 mL/min): No dose adjustment is required; standard therapeutic dosing may be used. (ACC/AHA) 5
Timing of Transition
- Immediate switch: Discontinue the heparin infusion and give the first enoxaparin dose without any washout period or overlap; aPTT normalization is not required before initiating enoxaparin. (ACC/AHA) 8
Safety Monitoring
- Baseline assessment: Obtain a baseline hemoglobin/hematocrit before the transition to identify patients at higher risk of bleeding. (ACC/AHA) 9
Duration of Therapy
- Minimum treatment length: At least 48 hours of anticoagulation must be provided after the transition. (ACC/AHA) 5
- Hospitalization‑linked duration: Continue enoxaparin for the remainder of the index hospitalization, up to a maximum of 8 days, or until a planned revascularization procedure is performed. (ACC/AHA) 6
- Venous thromboembolism (VTE) overlap: When bridging to warfarin, maintain enoxaparin for a minimum of 5–7 days and continue it until the INR is therapeutic (2.0–3.0) on two consecutive days. (American Society of Clinical Oncology guideline) 10
Pitfalls to Avoid
- Renal dose omission: Failure to reduce enoxaparin dosing in patients with severe renal impairment (CrCl < 30 mL/min) markedly increases the risk of major bleeding. (ACC/AHA) 7